Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9635-9641

  Li, Xing ^a   Zhong, Xiang ^b   Chen, Zhan Hong ^a   Xing, Yan Fang ^a   Wu, Dong Hao ^a   Chen, Jie ^a   Ma, Xiao Kun ^a   Lin, Qu ^a   Wen, Jing Yun ^a   Wei, Li ^a   Wang, Tian Tian ^a   Ruan, Dan Yun ^a   Lin, Ze Xiao ^a   Wu, Xiang Yuan ^a   Dong, Min ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; prognostic analysis; Transcatheter arterial chemoembolization

Indexed keywords

EID: 84921530813     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9635     Document Type: Article

References (25)

1. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
2. Eltawil KM, Berry R, Abdolell M, et al (2012). Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB, 14, 162-70.
3. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatology, 53, 1854-63.
4. Huang ZL, Luo J, Chen MS, et al (2011). Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol, 22, 702-9.
5. Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35.
6. Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40.
7. Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9.
8. Lao XM, Luo G, Ye LT, et al (2013). Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int, 33, 595-604.
9. Lencioni R, Llovet JM (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 30, 52-60.
10. Li H, Hu Y, Li N, et al (2012a). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93.
11. Li SH, Guo ZX, Xiao CZ, et al (2013a). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63.
12. Li X, Dong M, Lin Q, et al (2013b). Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol, 9, 86-92.
13. Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85.
14. Li X, Xing YF, Lin Q, et al (2012b). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350
15. Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85.
16. Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatology, 50, 661-2.
17. Murata S, Mine T, Ueda T, et al (2013). Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal, 2013, 479805.
18. Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75.
19. Scartozzi M, Faloppi L, Bianconi M, et al (2012). The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One, 7, 32653.
20. Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66.
21. Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000.
22. Wang Y, Chen Y, Ge N, et al (2012). Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol, 19, 3540-6.
23. Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18.
24. Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7.
25. Yu SJ, Lee JH, Jang ES, et al (2013). Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology, 267, 638-47.